New pill combo aims to slash cholesterol in High-Risk patients

NCT ID NCT07219602

Recruiting now Disease control Sponsor: NewAmsterdam Pharma Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study tests whether a daily pill combining obicetrapib and ezetimibe, or obicetrapib alone, can lower LDL (bad) cholesterol more than placebo in 300 people with type 2 diabetes or metabolic syndrome. Participants continue their standard cholesterol medications. The main goal is to measure cholesterol changes after 84 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obicetrapib and ezetimibe (fixed-dose combination or obicetrapib alone)
What this could lead to: If successful, this could provide a new daily pill option to better control cholesterol in people with diabetes or metabolic syndrome, reducing heart disease risk.
What could go wrong: This is a Phase 3 trial, but results may not apply to everyone. Side effects or lack of significant benefit over existing treatments are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome hyperlipidemia metabolic syndrome X type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPIDEMIA METABOLIC SYNDROME (METS) TYPE 2 DIABETES (T2DM)

Contacts and locations

Locations

Burke Internal Medicine
RECRUITING

Burke, Virginia, 22015-2234, United States
Burke International Medicine DBA Manassas Clinical Research Center
RECRUITING

Manassas, Virginia, 20110, United States
Central New York Clinical Research
RECRUITING

Manlius, New York, 13104, United States
Centricity Research dba Lucas Research
RECRUITING

Morehead City, North Carolina, 28557, United States
Clinical Research Institute of Arizona
RECRUITING

Sun City West, Arizona, 85375, United States
Clinical Trials of Texas dba Flourish Research
RECRUITING

San Antonio, Texas, 78229, United States
East Coast Institute of Research LLC
RECRUITING

Jacksonville, Florida, 32216, United States
East Coast Institute of Research LLC
RECRUITING

Lake City, Florida, 32055, United States
Floridian Clinical Research
RECRUITING

Miami Lakes, Florida, 33016, United States
Floridian Clinical Research
RECRUITING

Greensboro, North Carolina, 27408, United States
Inspira Health - Internal Medicine Associates
RECRUITING

Bridgeton, New Jersey, 08302, United States
Jefferson City Medical Group
RECRUITING

Jefferson City, Missouri, 65109, United States
Juno Research LLC - Medical Center
RECRUITING

Houston, Texas, 77054, United States
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
RECRUITING

Louisville, Kentucky, 40213, United States
MD Medical Research
RECRUITING

Oxon Hill, Maryland, 20745, United States
Montana Medical Research
RECRUITING

Missoula, Montana, 59808, United States
Scripps Health - Whittier Diabetes Institute
RECRUITING

La Jolla, California, 92037, United States
Summit Research Group
RECRUITING

Munroe Falls, Ohio, 44262, United States
UF Health Jackson
RECRUITING

Jacksonville, Florida, 32209, United States
Velocity Clinical Research
RECRUITING

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.